Silk Road Medical, Inc (SILK)
27.49
0.00 (0.00%)
Inactive · Last trade price on Sep 17, 2024
Silk Road Medical Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Silk Road Medical stock had an average target of 24, with a low estimate of 20 and a high estimate of 27.5.
Price Target: $24 (-12.7%)
Analyst Consensus: Hold
No price target forecast data available
* Price targets were last updated on Jul 17, 2024.
Analyst Ratings
The average analyst rating for Silk Road Medical stock from 5 stock analysts was "Hold". This means that analysts believed this stock was likely to perform similarly to the overall market.
Recommendation Trends
| Rating | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 2 | 0 | 0 | 0 | 0 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 5 | 6 | 7 | 7 | 7 | 4 |
| Sell | 1 | 1 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 2 | 2 | 2 | 1 |
| Total | 12 | 11 | 10 | 10 | 10 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel | Stifel | Strong Buy → Hold Downgrades $23 → $28 | Strong Buy → Hold | Downgrades | $23 → $28 | +0.04% | Jul 17, 2024 |
| Argus Research | Argus Research | Strong Buy → Strong Sell Downgrades n/a | Strong Buy → Strong Sell | Downgrades | n/a | n/a | Jul 11, 2024 |
| Lake Street | Lake Street | Strong Buy → Hold Downgrades $28 → $28 | Strong Buy → Hold | Downgrades | $28 → $28 | +0.04% | Jun 18, 2024 |
| JP Morgan | JP Morgan | Hold Maintains $19 → $21 | Hold | Maintains | $19 → $21 | -23.61% | May 1, 2024 |
| Piper Sandler | Piper Sandler | Hold Maintains $18 → $20 | Hold | Maintains | $18 → $20 | -27.25% | May 1, 2024 |
Financial Forecast
Revenue This Year
203.98M
from 177.13M
Increased by 15.16%
Revenue Next Year
226.77M
from 203.98M
Increased by 11.17%
EPS This Year
-1.49
from -1.44
EPS Next Year
-1.34
from -1.49
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 214.2M | 236.7M | 264.7M |
| Avg | 204.0M | 226.8M | 249.3M |
| Low | 193.2M | 212.2M | 232.3M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 20.9% | 16.0% | 16.7% |
| Avg | 15.2% | 11.2% | 9.9% |
| Low | 9.1% | 4.0% | 2.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -1.51 | -1.28 | -1.12 |
| Avg | -1.49 | -1.34 | -1.26 |
| Low | -1.46 | -1.38 | -1.31 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.